| 51 |
29297709 | Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia. | 2018 Mar |
1 |
| 52 |
29311539 | Tolvaptan for Fluid Management in Living Donor Liver Transplant Recipients. | 2018 Jan 9 |
1 |
| 53 |
29430193 | Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. | 2018 |
1 |
| 54 |
29467353 | Can Tolvaptan Protect Renal Function in the Early Postoperative Period of Cardiac Surgery? - Results of a Single-Center Randomized Controlled Study. | 2018 Mar 23 |
1 |
| 55 |
29970015 | Case report: a thiazide diuretic to treat polyuria induced by tolvaptan. | 2018 Jul 3 |
2 |
| 56 |
30147354 | Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload. | 2018 |
1 |
| 57 |
30563565 | Impact of continued administration of tolvaptan on cirrhotic patients with ascites. | 2018 Dec 18 |
1 |
| 58 |
31315326 | Efficacy and Safety of Oral Tolvaptan Therapy in Hospitalized Cirrhotic Patients with Hyponatremia. | 2018 Dec |
1 |
| 59 |
27339446 | Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients. | 2017 Jun |
1 |
| 60 |
27363974 | Treatment for cirrhotic ascites. | 2017 Feb |
1 |
| 61 |
27448501 | Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema. | 2017 May |
2 |
| 62 |
27655350 | Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. | 2017 Jan |
1 |
| 63 |
27670393 | Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites. | 2017 Aug |
1 |
| 64 |
27704665 | Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. | 2017 Aug |
1 |
| 65 |
27856088 | Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. | 2017 Feb |
1 |
| 66 |
27943449 | Investigation and comparison of the binding between tolvaptan and pepsin and trypsin: Multi-spectroscopic approaches and molecular docking. | 2017 May |
1 |
| 67 |
28166521 | Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. | 2017 |
1 |
| 68 |
28194574 | Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease. | 2017 May |
1 |
| 69 |
28218410 | Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial. | 2017 Jul |
1 |
| 70 |
28251822 | Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. | 2017 Apr |
1 |
| 71 |
28614813 | Polycystic Kidney Disease and the Vasopressin Pathway. | 2017 |
1 |
| 72 |
28943585 | The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan. | 2017 Nov 15 |
1 |
| 73 |
29105594 | Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. | 2017 Nov 16 |
1 |
| 74 |
29145907 | [Autosomal dominant polycystic kidney disease: should patients' young adult relatives be screened or not?] | 2017 |
1 |
| 75 |
29399022 | Edematous Hyponatremia Treated with Tolvaptan in a Patient with Amyotrophic Lateral Sclerosis. | 2017 Dec |
1 |
| 76 |
26072263 | Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size. | 2016 Feb |
1 |
| 77 |
26123753 | Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis. | 2016 Mar |
1 |
| 78 |
26507107 | Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury? | 2016 Jan |
1 |
| 79 |
26676672 | Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. | 2016 Oct |
1 |
| 80 |
26710331 | Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH). | 2016 Feb 15 |
1 |
| 81 |
26742881 | Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure. | 2016 |
2 |
| 82 |
26908832 | Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. | 2016 Mar |
1 |
| 83 |
26912543 | Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. | 2016 May 6 |
2 |
| 84 |
27184496 | Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. | 2016 May 16 |
1 |
| 85 |
27395406 | Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment. | 2016 Oct |
1 |
| 86 |
27540244 | TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE. | 2016 Sep |
1 |
| 87 |
27591907 | Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass. | 2016 Dec |
1 |
| 88 |
27746425 | Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis. | 2016 |
1 |
| 89 |
27818782 | Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. | 2016 Sep |
1 |
| 90 |
27857840 | Tolvaptan use during hyperhydration in paediatric intracranial lymphoma with SIADH. | 2016 |
1 |
| 91 |
27921039 | Clinical Manifestation and Management of ADPKD in Western Countries. | 2016 Oct |
1 |
| 92 |
25429910 | Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis. | 2015 Nov |
1 |
| 93 |
25543187 | Exploring urinary biomarkers in autosomal dominant polycystic kidney disease. | 2015 Oct |
1 |
| 94 |
25600953 | Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. | 2015 Jun |
1 |
| 95 |
25734677 | [Syndrome of inadequate ADH secretion: pitfalls in diagnosis and therapy]. | 2015 Mar |
1 |
| 96 |
25740399 | Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure. | 2015 |
1 |
| 97 |
25926290 | Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. | 2015 |
1 |
| 98 |
25997504 | Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study. | 2015 Jul |
1 |
| 99 |
26148383 | The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. | 2015 Apr |
1 |
| 100 |
26407729 | Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. | 2015 Oct |
1 |